English   español  
Please use this identifier to cite or link to this item: http://hdl.handle.net/10261/109990
logo share SHARE logo core CORE   Add this article to your Mendeley library MendeleyBASE

Visualizar otros formatos: MARC | Dublin Core | RDF | ORE | MODS | METS | DIDL | DATACITE
Exportar a otros formatos:


Detection of cancer biomarkers in serum using a hybrid mechanical and optoplasmonic nanosensor

AuthorsKosaka, Priscila M. ; Pini, Valerio ; Ruz Martínez, José Jaime ; Silva, Rubens A. da; González Sagardoy, María Ujué ; Ramos Vega, Daniel ; Calleja, Montserrat ; Tamayo de Miguel, Francisco Javier
Issue Date2-Nov-2014
PublisherNature Publishing Group
CitationNature Nanotechnology 9: 1047–1053 (2014)
AbstractBlood contains a range of protein biomarkers that could be used in the early detection of disease. To achieve this, however, requires sensors capable of detecting (with high reproducibility) biomarkers at concentrations one million times lower than the concentration of the other blood proteins. Here, we show that a sandwich assay that combines mechanical and optoplasmonic transduction can detect cancer biomarkers in serum at ultralow concentrations. A biomarker is first recognized by a surface-anchored antibody and then by an antibody in solution that identifies a free region of the captured biomarker. This second antibody is tethered to a gold nanoparticle that acts as a mass and plasmonic label; the two signatures are detected by means of a silicon cantilever that serves as a mechanical resonator for ‘weighing’ the mass of the captured nanoparticles and as an optical cavity that boosts the plasmonic signal from the nanoparticles. The capabilities of the approach are illustrated with two cancer biomarkers: the carcinoembryonic antigen and the prostate specific antigen, which are currently in clinical use for the diagnosis, monitoring and prognosis of colon and prostate cancer, respectively. A detection limit of 1 × 10−16 g ml−1 in serum is achieved with both biomarkers, which is at least seven orders of magnitude lower than that achieved in routine clinical practice. Moreover, the rate of false positives and false negatives at this concentration is extremely low, ∼10−4.
Publisher version (URL)http://dx.doi.org/10.1038/nnano.2014.250
Appears in Collections:(IMN-CNM) Artículos
Files in This Item:
File Description SizeFormat 
cancer_biomarkers_Kosaka.pdf1,35 MBAdobe PDFThumbnail
Show full item record
Review this work

WARNING: Items in Digital.CSIC are protected by copyright, with all rights reserved, unless otherwise indicated.